Lung cancers often harbour loss-of-function mutations in SMARCA4. Here, the authors demonstrate a vulnerability of SMARCA4-deficient lung cancers for Aurora kinase A inhibition associated with mitotic defects. Here, SMARCA4 is linked to lung carcinoma.